Functional Precision Medicine by Design

Targeted therapies do not work for everyone

Single Drug Therapies
20%
Targeted Therapies
25-75%
Immunotherapies
20-40%

Every 4 week delay in cancer treatment causes up to 28% increase in mortality risk.

It's all possible now
through Nine Diagnostics.

A faster path to the most effective treatment with better outcomes

We develop holistic profiles based on a patient’s personal health data, demographics, social determinants of health, and other relevant factors pertinent to the ultimate outcomes.
Multidimensional datasets are acquired from fluorescent emissions using an array of nanoscale sensing elements that detect health abnormalities and signals of treatment effectiveness in small patient samples.​
Get patients the most effective treatment faster by providing feedback to select and optimize treatment faster.
Researchers and drug developers can now understand new biology with biomarkers that react dynamically, in real time, directly from patients.
Clinicians can accelerate validation of precision medical treatments in real patient situations.
Patients ultimately get the most effective treatment as soon as possible.

Shorter closed feedback loops save lives

December 19, 2024
Nine Diagnostics Co-Founder Daniel Heller Discusses AI-Enabled Nanosensor Technology for Gynecological Health in BBC News!

“What we’d like to do is triage all gynaecological disease – so when someone comes in with a complaint, can we give doctors a tool that quickly tells them it’s more likely to be a cancer or not, or this cancer than that.” -Daniel Heller

AI is trained to spot warning signs in blood tests

November 27, 2024
Nine Diagnostics engages in U.S. - Dutch Consortium Collaboration in Women's Health

Building Novel Solutions for Women's Health

Leading Dutch and U.S. companies are joining forces to develop groundbreaking diagnostic tools and treatments in gynecological health.

The collaboration is supported by the Netherlands Innovation Network in Boston - Dutch Ministry of Economic Affairs.

November 14, 2024
Nine Diagnostics Selected for Merck Digital Sciences Studio Cohort 3

MDSS - Nine Diagnostics

Nine Diagnostics is proud to announce its acceptance into the latest cohort of the Merck Digital Sciences Studio (MDS Studio), a digital accelerator designed to enable the next generation of technologies for drug discovery and development, including artificial intelligence and machine learning. MDS Studio was founded to offer support for early-stage biomedical startups providing strategic guidance, direct investment, and connection opportunities within Merck.

Nine Diagnostics Selected for Merck Digital Sciences Studio Cohort 3 - Nine Diagnostics

October 6, 2024
Nine Diagnostics Selected in the Inaugural Cohort for CancerHackerLab Accelerator!
September 19, 2024
Nine Diagnostics Wins Novo Nordisk Golden Ticket for LabCentral Residency

Nine Diagnostics, a leader in cutting-edge medical diagnostics, is honored to announce that it has been awarded the Novo Nordisk Golden Ticket for a residency at LabCentral, hosted by the Novo Nordisk Bio Innovation Hub. This incredible opportunity is a significant milestone for the company, reinforcing its commitment to improving healthcare through advanced technologies that enable faster, more personalized diagnostics.

Nine Diagnostics Wins Novo Nordisk Golden Ticket for LabCentral Residency - Nine Diagnostics

September 13, 2024
Nine Diagnostics Selected to Participate in the Engine's Blueprint Program
July 17, 2024
Nine Diagnostics Selected to Participate in NSF I-Corps Program at MIT
March 8, 2024
Nine Diagnostics is Born